BioNTech: watchdogs' requirements may defer planned launch of Omicron shot

1 minute read

Vials labelled "VACCINE Coronavirus COVID-19" and a syringe are seen in front of a displayed Biontech logo in this illustration taken December 11, 2021. REUTERS/Dado Ruvic/Illustration

Register now for FREE unlimited access to Reuters.com

FRANKFURT, Jan 25 (Reuters) - BioNTech (22UAy.DE) said it and partner Pfizer (PFE.N) may not be able to stick with their plan to launch an Omicron-targeting vaccine by the end of March, depending on how much clinical trial data regulators will require.

"Regulatory requirements are currently under discussion with the relevant authorities. Inclusion of clinical trial data in the regulatory filings may have an impact on the delivery of initial batches, currently expected to be ready by end of March," a spokesperson told Reuters on Tuesday.

Pfizer and BioNTech said earlier they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen. read more

Register now for FREE unlimited access to Reuters.com
Reporting by Ludwig Burger, Editing by Louise Heavens

Our Standards: The Thomson Reuters Trust Principles.